Last reviewed · How we verify
Hairy cell leukemia
Approved treatments
- Intron A · Merck & Co.
- Nipent · Hospira Inc
- Sitravatinib · Pfizer
- Lumoxiti · AstraZeneca
- Leustatin
Leustatin works by inhibiting the enzyme that breaks down cyclic adenosine monophosphate (cAMP), leading to an accumulation of cAMP and subsequent activation of various cellular pathways. - Deoxycoformycin · Boston Medical Center
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Hairy cell leukemia patent landscape — cliff calendar, originator estates, attackable patents
- Hairy cell leukemia treatment landscape brief
- Hairy cell leukemia treatment updates RSS
Frequently asked questions about Hairy cell leukemia
What drugs treat Hairy cell leukemia?
Tracked treatments include Intron A, Nipent, Sitravatinib, Lumoxiti, Leustatin, Deoxycoformycin.
What is the treatment for Hairy cell leukemia?
Standard treatment for Hairy cell leukemia includes Intron A, Nipent, Sitravatinib, Lumoxiti, Leustatin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Hairy cell leukemia patent cliff · Hairy cell leukemia CI report
- Treatment: Intron A · Merck & Co.
- Treatment: Nipent · Hospira Inc
- Treatment: Sitravatinib · Pfizer
- Treatment: Lumoxiti · AstraZeneca
- Treatment: Leustatin
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing